Publications

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – a post-hoc analysis of a Phase 3, single-arm, open-label trial.

OBJECTIVE: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data …

The role of microparticles in inflammation and transfusion: a concise review

Abstract Microparticles are small membrane-bound vesicles, found in body fluids including peripheral blood. Microparticles are an intrinsic part of blood labile products delivered to transfused patients and have active roles in inflammation. They are delimited by a lipid bilayer composed mainly of phospholipids, cholesterol, membrane-associated proteins, intracellular components such as metabolic enzymes, proteins-involved …

Implementing American Heart Association Pediatric and Adult Nutrition Guidelines

A Scientific Statement From the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research Read More

Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features

Studyquestion: Are differences in androgen levels among women with various forms of ovarian dysfunction associated with cardiometabolic abnormalities? summaryanswer: Androgen levels differed substantially between women with and without ovarian dysfunction, and increased androgen levels were associated with impaired cardiometabolic features in all women irrespective of their clinical condition. what is …

Statin Intolerance: Diagnosis and Remedies

Abstract Despite the efficacy of statins in reducing cardiovascular events in both primary and secondary prevention, the adherence to statin therapy is not optimal, mainly due to the occurrence of muscular adverse effects. Several risk factors may concur to the development of statin-induced myotoxicity, including patient-related factors (age, sex, and race), statin properties (dose, …

Ezetimibe plus simvastatin for the treatment of hypercholesterolemia

Introduction: Cardiovascular disease is a major cause of death, and hypercholesterolemia is a major risk factor. Statins, with simvastatin among the most widely used, have ample evidence demonstrating prevention of cardiovascular events and mortality. Ezetimibe is effective at improving serum lipids in combination with statins or alone, but its role …

Ten-Year Follow-up After Initiation of Statin Therapy in ChildrenWith Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) is a prevalent (1:500 individuals) inherited disorder that strongly predisposes to premature atherosclerosisandsubsequent cardiovascular disease. In children with FH, atherosclerosis progression is observed before puberty. Consequently, guidelines for FH treatment advocate initiation of statins in childrenasyoung as8 years. However, longterm efficacy and safety data for statin therapy initiated during childhood do not exist.We …

Therapeutic algorithm for Patients with severe Hypercholesterolemia or isolated Lipoprotein(a)-Hyperlipoproteinemia with progressive cardiovascular disease: PCSK9-Inhibitors, Lipoprotein Apheresis or both?

Therapeutic algorithm for Patients with severe Hypercholesterolemia or isolated Lipoprotein(a)-Hyperlipoproteinemia with progressive cardiovascular disease: PCSK9-Inhibitors, Lipoprotein Apheresis or both? Nephrologisches Zentrum GöttingenGbR Priv. Doz. Dr.med. V. Schettler

EFFICACY OF ALIROCUMAB IN 1,191 PATIENTS WITH A WIDE SPECTRUM OF MUTATIONS IN GENES CAUSATIVE FOR FAMILIAL HYPERCHOLESTEROLEMIA

Authors: John J.P. Kastelein, Gisle Langslet, Paul Hopkins, Joep Defesche, Werner Seiz, Marie Baccara-Dinet, Sara Hamon, Poulabi Banerjee, Claudia Stefanutti, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, Sanofi, Montpellier, France Background: Next Generation Sequencing was performed to examine treatment response with alirocumab in patients carrying one or more causative mutation(s) in five familial …

Efficacy of Alirocumab in 1191 Patients with a Wide Spectrum of Mutations in Genes Causative for Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) is characterized by high levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of developing premature coronary heart disease. The prevalence of heterozygous and homozygous FH has been estimated to be 1:200 to 1:500 and 1:160,000 to 1:1,000,000, respectively. In plasma, LDL-C levels are regulated via apolipoprotein …

Category Archives: Publications